Ziglip-M 50/500 Tablet is a fixed-dose combination medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, prolongs the activity of incretin hormones, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner. The combination of these two agents provides complementary mechanisms to effectively reduce fasting and postprandial blood glucose levels. Ziglip-M 50/500 is prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve adequate glycemic control. It is important to monitor renal function prior to initiation and periodically during therapy, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Vildagliptin is generally well tolerated but may rarely cause hypersensitivity reactions. Patients should be advised on lifestyle modifications and adherence to therapy to optimize outcomes. Regular monitoring of blood glucose and HbA1c levels is recommended to assess efficacy and safety.